Case-Control Study of Immunoglobulines and Pancreatic Enzyme Alterations in Covid-19 Iraqi Patients

Objective: C-reactive and Pancreatic enzymes changes for COVID-19 patients were estimated. Methods: Eighty individuals of both sexes, age range (28-69 y), with a mean±SE of (46.2±1.7) were included in this study, Group I: COVID-19 patients and Group II Aged matched healthy people as the control group. Venous blood samples were taken for each individual, serum collected and enzyme-linked immunosorbent assay technique (ELISA) was used to estimate the levels of C-reactive protein, lipase, and amylase, and we used a capture chemiluminescence immunoassay for IgM and an indirect chemiluminescence immunoassay for IgG. Results: The mean serum levels of IgM, IgG, CRP, were significantly higher in the patient group than in the control group (1.7 vs. 0.7 AU/ml, 2.86 vs. 0.27 AU/ml, 7.6 vs. 4 mg/dl) respectively and pancreatic enzymes (lipase, and amylase) were significantly higher in the patient group than in the control group (86 vs. 54U/l, and 66 vs. 39U/l), respectively. Conclusion, COVID-19 patients have an increased risk of exocrine secretion (lipase and amylase enzymes) and pancreatic damage. This work highlights the importance of pancreatic enzyme (amylase and lipase) estimation in affected patients.